Gene: IGFBP6
Official Full Name: insulin like growth factor binding protein 6provided by HGNC
Gene Summary: Enables identical protein binding activity and insulin-like growth factor II binding activity. Involved in cell migration and positive regulation of stress-activated MAPK cascade. Part of insulin-like growth factor binary complex. Implicated in obesity. Biomarker of breast cancer; in situ carcinoma; leiomyoma; and neovascular inflammatory vitreoretinopathy. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO37084 | IGFBP6 Knockout cell line (HeLa) | Human | IGFBP6 | 1:3~1:6 | Negative | Online Inquiry |
KO37085 | IGFBP6 Knockout cell line (HCT 116) | Human | IGFBP6 | 1:2~1:4 | Negative | Online Inquiry |
KO37086 | IGFBP6 Knockout cell line (HEK293) | Human | IGFBP6 | 1:3~1:6 | Negative | Online Inquiry |
KO37087 | IGFBP6 Knockout cell line (A549) | Human | IGFBP6 | 1:3~1:4 | Negative | Online Inquiry |
IGFBP6 Gene Knockout Cell Lines are genetically engineered cells that have had the insulin-like growth factor binding protein 6 (IGFBP6) gene entirely inactivated. This product serves as a critical tool for researchers studying the role of IGFBP6 in various biological processes, including cell growth, apoptosis, and tumorigenesis. By eliminating the expression of this specific protein, scientists can create a controlled environment to investigate the ramifications of IGFBP6 deficiency, offering insights into its complex interactions with insulin-like growth factors and other signaling pathways.
Key functions of IGFBP6 include modulating cellular responses to IGFs, influencing endocrine signaling, and affecting cellular proliferation. The knockout mechanism employed involves CRISPR-Cas9 technology, which allows precise editing of the genome, facilitating the study of gene function and the underlying molecular mechanisms in a robust and reproducible manner.
The scientific importance of IGFBP6 Gene Knockout Cell Lines extends into both research and clinical settings; they are invaluable for understanding disorders linked to IGF signaling, such as various cancers and metabolic diseases. These cell lines allow for high-throughput screening, functional studies of drug interactions, and the elucidation of potential therapeutic targets.
Compared to conventional cell lines, the IGFBP6 knockout model offers unparalleled specificity, enabling researchers to delineate the unique contributions of IGFBP6 without the confounding effects of its expression. Furthermore, the availability of these knockout lines positions researchers to generate more reliable data, ultimately fostering advancements in biomedical research and therapeutic development.
The advantages of it being a ready-to-use product, along with comprehensive support from our expert team, enhances the usability of IGFBP6 Gene Knockout Cell Lines for researchers and clinicians alike. Our commitment to excellence in developing cutting-edge biological products reflects our expertise and dedication to advancing scientific discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.